Skip to main content
SpringerLink
Log in

Lymphoproliferative Disorders

  • Reference work entry
  • First Online:
Geriatric Diseases

  • 1573 Accesses

Abstract

This review discusses the lymphoproliferative disorders, their prevalence and clinical management. Chronic lymphocytic leukaemia (CLL) is derived from mature B lymphocytes and is characterised by a progressive accumulation of lymphocytes in the blood, bone marrow and lymphatic tissues. CLL is a disease of the elderly. Antileukaemic therapy is frequently unnecessary in uncomplicated early disease. Non-Hodgkin’s lymphoma includes a diverse group of haematological causes which embraces any lymphoma other than Hodgkin’s lymphoma and by the absence of Reed-Sternberg cells. Hodgkin’s lymphoma (HL) is a malignant tumour of the lymphatic tissues and weakens the immune system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 379.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Klein U, Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol. 2010 20(6):377–83.

    Article  CAS  PubMed  Google Scholar 

  2. Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphatic leukaemia: the importance of age, sex and response to treatment in survival: a report from MRC CLL. Brit J Haemat. 1989;72(2) 141–149.

    Article  CAS  PubMed  Google Scholar 

  3. Rozman C, Montserrat E. Current concepts: Chronic lymphocytic leukaemia . NEJM. 1995;333:1052–1057.

    Article  CAS  PubMed  Google Scholar 

  4. Linet MS. Blattner WA. The epidemiology of chronic lymphocytic leukaemia. In Pollack A, Catovsky D eds Chronic Lymphocytic Leukaemia Switzerland: Hardwood Academic Publishers 1988: 11.

    Google Scholar 

  5. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics CA Cancer J Clin. 1998;48:6–29.

    Article  CAS  PubMed  Google Scholar 

  6. Linet MS, Cartwright RA. Chronic Lymphocytic leukaemia: epidemiology and etiologic findings. Nouv Rev Fr Haematol. 1988;30:353–357.

    CAS  Google Scholar 

  7. Kalil N, Cheson BD. Chronic lymphocytic leukaemia. The Oncologist. 1999;4 (5):S352–369.

    Google Scholar 

  8. Anaissie EJ, Kotoyiannis DP, O’Brien S, Kantarjian H, Robertson L, Lerner S, et al. Infections in patients with chronic lymphatic leukaemia treated with fludarabine. Ann Int Med. 1998;129(7):559–566.

    Article  CAS  PubMed  Google Scholar 

  9. Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune haemolytic anaemia in chronic lymphocytic leukaemia: clinical, therapeutic and prognostic features. Blood. 2000;95(9):2786–2792.

    CAS  PubMed  Google Scholar 

  10. Engelfriet CP, Overbeeke MAM, B Von den Borne AE. Autoimmune haemolytic anaemia. Semin Hematol. 1992;29:3–12.

    CAS  PubMed  Google Scholar 

  11. Tabhara IA. Hemolytic anaemias: diagnosis and management. Med Clin North Am. 1992;76:649–668.

    Article  Google Scholar 

  12. Cheson BD, Bennett IM, Kay N, Keating MJ, O’Brien S, Rai KR. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment. Blood. 1996;12:4990–4997.

    Google Scholar 

  13. Chronic lymphocytic leukaemia: recommendation for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukaemia. Ann Int Med. 1989;110(3):236–238.

    Google Scholar 

  14. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pastremack SS. Clinical staging of chronic lymphocytic leukaemia. Blood. 1975;46:219.

    CAS  PubMed  Google Scholar 

  15. Gibson J, Iland HJ, Larsen SR, Brown CMS, Joshua DE. Leukaemias into the 21st century-part 2: the chronic leukaemia. Int Med J. 2013; 43: 484–494.

    Article  CAS  Google Scholar 

  16. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer T, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphatic leukaemia: a randomised, open label, phase 3 trial. Lancet. 2010;276:1164–74.

    Google Scholar 

  17. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. NEJM. 2014;370:1101–10.

    Article  CAS  PubMed  Google Scholar 

  18. Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, et al. Allogenic stem-cell transplants may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukaemia. J Clin Oncol. 2005;23(15):3433–8.

    Article  PubMed  Google Scholar 

  19. Rolland-Portal I, Tazi MA, Milan C, Couillaut C, Carli PM. Non-Hodgkins lymphoma: time trends for incidence and survival in Cote- D’O r France. Int J Epidemiol. 1997;26(5): 945–952.

    Article  CAS  PubMed  Google Scholar 

  20. Young GAR, Iland HJ. Clinical perspectives in lymphoma. Int Med J. 2007;37:478–484.

    Article  CAS  Google Scholar 

  21. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(3): 803–43.

    Article  CAS  PubMed  Google Scholar 

  22. Pfreundschuh M, Trumper L, Osterburg A, Pettengell R, Tmery M, Imrie K, et al. CHOP like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in younger patients with good prognosis diffuse large B-cell lymphoma: a randomized controlled trial by Mabthera International Trial (MinT) Group. Lancet Oncol. 2006;7:379–391.

    Article  CAS  PubMed  Google Scholar 

  23. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bonabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groups d’etude des Lymphomes d’Adulte. J Clin Oncol. 2005; 23:4117–26.

    Article  CAS  PubMed  Google Scholar 

  24. SEER. Stat Fact Sheet: Hodgkins lymphoma. National Cancer Institute. http://seer.cancer.gov/statfacts/htm/hodg.html. accessed 16 February 2015.

  25. Poppema S. Immunobiology and pathophysiology of Hodgkin’s lymphoma. ASH Education Book. 2005;1:231–238. http://asheducationbook.hematologylibrary.org/content/2005/1/231. full accessed on 23/05/2012.

  26. Schwarzer R, Jundt F. Notch and NF-kB signalling pathways in the biology of classical Hodgkin lymphoma. Curr Mol Med 2011;11(3):26–45.

    Article  Google Scholar 

  27. Harris NL. Hodgkin’s disease: classification and differential diagnosis. Mod Pathol 1999;12(2):159–7.

    CAS  PubMed  Google Scholar 

  28. Foss HD, Msarafioti T, Stein H. Hodgkin lymphoma. Classification and pathogenesis. Pathologe. 2000;21(2):113–23.

    Article  CAS  PubMed  Google Scholar 

  29. Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin’s lymphoma. J Clin Oncol. 2005;23(26):6379–86.

    Article  CAS  PubMed  Google Scholar 

  30. Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology. 2011;58(1):15025.

    Article  Google Scholar 

  31. Gruss HJ, Kadin ME. Pathophysiology of Hodgkin’s disease: functional and molecular aspects. Baillieres Clin Haematol. 1996;9(3): 417–46.

    Article  CAS  PubMed  Google Scholar 

  32. Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin and Reed/Sternberg cells in Hodgkin’s lymphoma. In J Cancer. 2006;118(8):1853–61.

    Google Scholar 

  33. Hardell L, Axelson O. Environmental and occupational aspects on the etiology of non-Hodgkin’s lymphoma.Oncol Res. 1998;10(1):1–5.

    CAS  PubMed  Google Scholar 

  34. Mesa R, Miller CB, Thyme M, Mangan J, Goldberg S, Fazal S, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity, the MPN Landmark Survey. BMC Cancer. 2026;16:67. https://doi.org/10.1186/s12885-016-2208-2.

  35. Hameed A, Brady JJ, Dowling P, Clynes M, O’Gorman P. Bone disease in multiple myeloma: Pathophysiology and management. Cancer Growth and Metastasis. 2014;7:33–42.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Allart-Vorelli P, Porro B, Baguet F, Michel A, Cosson-Glie F. Haematological cancer and quality of life: a systematc literature review. Blood Cancer J. 2015;5,e305; https://doi.org/10.1038/bcj.2015.29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Hassan M, Abedi-Vahegerd M. Haematological malignancies in elderly patients. Haematologica. 2014;99:1124–1127.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Nargaard M, Larsson H, Pedersen G, Schenheyder HC, Rothman KJ, Serensen HY. Short-term mortality of bacteraemia in elderly patients with haematological malignancies. Br J Haematol. 2006;132:(9):25–31.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Sydney, Westmead Clinical School, Westmead, NSW, Australia

    Nages Nagaratnam & Kujan Nagaratnam

  2. Rehabilitation and Aged Care Service, Blacktown-Mt Druitt Hospital, Mount Druitt, NSW, Australia

    Gary Cheuk

Authors
  1. Nages Nagaratnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kujan Nagaratnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary Cheuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nagaratnam, N., Nagaratnam, K., Cheuk, G. (2018). Lymphoproliferative Disorders. In: Geriatric Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-33434-9_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33434-9_26

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33433-2

  • Online ISBN: 978-3-319-33434-9

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation